论文部分内容阅读
临床发生率最高的消化道恶性肿瘤之一为胃癌,有较高发生率与死亡率。临床治疗晚期胃癌主要采用化学疗法,尚未研发出类型多样且疗效确切的靶向治疗药物。因胃癌具有强效异质性,为此临床十分关注寻找关联于胃癌发生、预后的分子标志物。胃癌发生发展可能有独特的分子生物学背景,在胃癌组织中LKB1及ARID1A有70~80%的突变率,故而临床十分关注这两个因子在胃癌中的作用及对预后的影响,现综述如下。
One of the most clinically occurring gastrointestinal malignancies is gastric cancer, with a high incidence and mortality. Clinical treatment of advanced gastric cancer mainly by chemotherapy, has not yet developed a variety of types and the exact effect of targeted therapies. Due to the strong heterogeneity of gastric cancer, this clinic is very concerned about looking for molecular markers associated with the occurrence and prognosis of gastric cancer. The occurrence and development of gastric cancer may have a unique molecular biology background. The mutation rates of LKB1 and ARID1A in gastric cancer are 70-80%. Therefore, the clinical significance of these two factors in gastric cancer and the prognosis is summarized as follows .